Analysis of dyslipidemia in people living with HIV

Authors

DOI:

https://doi.org/10.15649/cuidarte.v10i2.776

Keywords:

HIV Infections, Dyslipidemias, Risk Factors, Cardiovascular Diseases, Acquired Immudeficiency Syndrome

Abstract

Introduction: In the context of people living with HIV (PLHIV), dyslipidemia is an issue that has been widely discussed, both because of its multifactorial origin and its cardiovascular implications as well as because of its possible prevention strategies. Thus, this study aims to assess the presence of dyslipidemia in people living with HIV and its association with socio-demographic, attitudinal and clinical aspects. Materials and Methods: An analytical cross-sectional study was conducted between 2014 and 2016. The data were collected through interviews in which questionnaires and clinical records were used. To analyze the association, Chi-Squared and Fisher’s Exact tests and Kappa statistics were used for concordance analysis with a level of significance of p<0.05. Results: 340 individuals participated in the study of which 59.1% showed desirable values in terms of total cholesterol, 55.9% of HDL and 56.8% of triglycerides. The variables associated with dyslipidemia were: altered total cholesterol and being over 40 years old (p=0.02); desirable HDL-C and female sex (p=0.007); altered triglycerides and time of diagnosis greater than ten years (p=0.008); and desirable HDL-C and undetectable viral load (p=0.04). Discussion: Although dyslipidemia is a problem in the HIV context, the desirable values were more prevalent, which is reflected in the catalytic effect of the HIV-caused inflammatory activity on lipid alterations. Conclusions: Dyslipidemia on people living with HIV mainly showed desirable values for total cholesterol, HDL cholesterol and triglycerides. There was an association between lipids and socio-demographic and clinical aspects related to VIH.

Como citar este artigo: Melo ES, Costa CRB, Foresto JS, Antonini M, Pontes PS, Reis RK. Análise da dislipidemia em adultos vivendo com HIV. Rev Cuid. 2019; 10(2): e776. http://dx.doi.org/10.15649/cuidarte.v10i2.776

Author Biographies

Elizabete Santos Melo, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Doutoranda no Prgrama de Pós-Graduação Enfermagem Fundamental, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Christefany Régia Braz Costa, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Doutoranda no Prgrama de Pós-Graduação Enfermagem Fundamental, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Marcela Antonini, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Aluna de graduação do Curso de Enfermagem da Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Priscila Silva Pontes, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Mestranda do Programa de Pós-Graduação Enfermagem Fundamental da Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Renata Karina Reis, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Professora Associada do Curso de Enfermagem da Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo

Dislipidemia em pessoas vivendo com HIV: prevalência, associação e concordância entre variáveis

References

Ministério da Saúde, Brasil. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em adultos. Brasília, 2018. 412p.

UNAIDS. Join United Nations Programme on HIV/Aids. Global AIDS Update-Ending AIDS: progress towards the 90-90-90 targets. Geneva, 2017. 196p.

Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One. 2016; 11(3): e0150970. https://doi.org/10.1371/journal.pone.0150970

Schulte-Hermann K, Schalk H, Haider B, Hutterer J, Gmeinhart B, Pichler K, et al. Impaired lipid profile and insulin resistance in a cohort of Austrian HIV patients. J Infect Chemother. 2016; 22(4): 248-53. http://dx.doi.org/10.1016/j.jiac.2016.01.007

Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis. 2017; 17(1): 551. http://dx.doi.org/10.1186/s12879-017-2626-z

Echecopar-Sabogal J, D'Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. Int J STD AIDS. 2018; 29(5): 443-52. http://dx.doi.org/10.1177/0956462417732226

Godoi ETAM, Brandt CT, Lacerda HR, Godoi JTAM, Oliveira DC, Costa GFAS, et al. Espessamento Mediointimal nas Carótidas e Femorais para Detectar Aterosclerose em Pessoas que Vivem com o Vírus da Imunodeficiência Humana. Arq Bras Cardiol. 2017; 108(1): 3-11. http://dx.doi.org/10.5935/abc.20160197

Beraldo RA, Meliscki GC, Silva BR, Navarro AM, Bollela VR, Schmidt A, et al. Comparing the Ability of Anthropometric Indicators in Identifying Metabolic Syndrome in HIV Patients. PLoS One. 2016; 11(2): e0149905. http://dx.doi.org/10.1371/journal.pone.0149905

Ximenes RA, Lacerda HR, Miranda-Filho DB, Albuquerque M de F, Montarroyos UR, Turchi MD, et al. Comparison between potential risk factors for cardiovascular disease in people living with HIV/AIDS in areas of Brazil. J Infect Dev Ctries. 2015; 9(9): 988-96. http://dx.doi.org/10.3855/jidc.5867

Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A Neto. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017; 109(2Supl1):1-76. http://dx.doi.org/10.5935/abc.20170121

WHO. World Health Organization. Global action plan on physical activity 2018–2030: more active people for a healthier world. Genebra, 2018. 101p.

Ministério da Saúde, Brasil. Guia Alimentar. Como ter uma alimentação. 1.ed. Brasília, 2013. 31p.

Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1): 159-74. http://dx.doi.org/10.2307/2529310

Nguyen KA, Peer N, Mills EJ, Kengne AP. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One. 2016; 11(3): e0150970. http://dx.doi.org/10.1371/journal.pone.0150970

Akl LD, Valadares ALR, Moraes MJ, Pinto-Neto AM, Lagrutta B, Costa-Paiva L. Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factors. Braz J Infect Dis. 2017; 21(3): 263-69. http://dx.doi.org/10.1016/j.bjid.2017.02.003

Gomes R, Murta D, Facchini R, Meneghel SN. Gender and sexual rights: their implications on health and healthcare. Ciênc saúde coletiva. 2018; 23(6): 1997-2006. http://dx.doi.org/10.1590/1413-81232018236.04872018

Levy ME, Greenberg AE, Hart R, Happ LP, Hadigan C, Castel C, et al. High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC. HIV Med. 2017; 18(10): 724-35. http://dx.doi.org/10.1111/hiv.12516

Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep. 2014; 11(3): 271-8. http://dx.doi.org/10.1007/s11904-014-0219-7

Obirikorang C, Quaye L, Osei-Yeboah J, Odame EA, Asare I. Prevalence of metabolic syndrome among HIV-infected patients in Ghana: A cross-sectional study. Niger Med J. 2016; 57(2): 86-90. http://dx.doi.org/10.4103/0300-1652.182082

Justina LB, Luiz MC, Maurici R, Schuelter-Trevisol F. Prevalence and factors associated with lipodystrophy in AIDS patients. Rev Soc Bras Med Trop. 2014; 47(1): 30-7. http://dx.doi.org/10.1590/0037-8682-0240-2013

Amberbir A, Banda V, Singano V, Matengeni A, Pfaff C, Ismail Z, et al. Effect of cardio-metabolic risk factors on all-cause mortality among HIV patients on antiretroviraltherapy in Malawi: A prospective cohort study. PLoS One. 2019; 14(1): e0210629. https://doi.org/10.1371/journal.pone.0210629

Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep. 2014; 11(3): 271-8. http://dx.doi.org/10.1007/s11904-014-0219-7

Nadel J, Holloway CJ. Screening and risk assessment for coronary artery disease in HIV infection: an unmet need. HIV Med. 2017; 18(4): 292-9. http://dx.doi.org/https://doi.org/10.1111/hiv.12422

Hemkens LG, Bucher HC. HIV infection and cardiovascular disease. Eur Heart J. 2014; 35(21): 1373-81. http://dx.doi.org/10.1093/eurheartj/eht528

Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta analysis. HIV Med. 2017; 18(4): 256-66. http://dx.doi.org/10.1111/hiv.12421

Fernández-Silva CA, Lopez-Andrade CI, Merino C. Adherencia al tratamiento antirretroviral como conducta promotora de salud en adultos mayores. Rev Cuid. 2018; 9(2): 2201-14. http://dx.doi.org/10.15649/cuidarte.v9i2.522

Published

2019-05-03

How to Cite

1.
Melo ES, Costa CRB, Foresto JS, Antonini M, Pontes PS, Reis RK. Analysis of dyslipidemia in people living with HIV. Revista Cuidarte [Internet]. 2019 May 3 [cited 2024 Nov. 24];10(2). Available from: https://revistas.udes.edu.co/cuidarte/article/view/776

Issue

Section

Investigation Article

Altmetrics

Downloads

Download data is not yet available.

Most read articles by the same author(s)